Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apremilast - Amgen

Drug Profile

Apremilast - Amgen

Alternative Names: CC-10004; CC-1004; OTEZLA; Otezla

Latest Information Update: 28 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Amgen; Baylor Research Institute; Celgene Corporation; Erasmus MC
  • Class Acetamides; Anti-inflammatories; Antineoplastics; Antipsoriatics; Isoindoles; Phthalimides; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Behcet's syndrome; Plaque psoriasis; Psoriatic arthritis
  • Phase III Ankylosing spondylitis; Immunological disorders; Psoriasis
  • Phase II Atopic dermatitis; Bullous pemphigoid; Eczema; Female genital diseases; Hidradenitis suppurativa; Palmoplantar pustulosis; Ulcerative colitis
  • Clinical Phase Unknown COVID 2019 infections
  • No development reported Rheumatoid arthritis
  • Discontinued Asthma; Cancer; Crohn's disease

Most Recent Events

  • 26 Oct 2020 Phase-III clinical trials in Immunological disorders (suppression of cytokine storm in patients with COVID-2019 infections) in USA (unspecified route) before October 2020
  • 21 Oct 2020 Amgen plans a phase III trial for COVID-2019 infections (Combination therapy) (PO) in October 2020 (EudraCT2020-002594-10) (NCT04590586)
  • 27 Aug 2020 Amgen plans the phase III BEAN trial in Behcet's disease (oral ulcers associated with Behcet's disease) (In children, In adolescents) (PO) in April 2021 (NCT04528082)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top